Literature DB >> 8124580

Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation.

W H Church1, V L Ward.   

Abstract

Postmortem caudate and substantia nigra tissue samples from human parkinsonian patients (PD) and age-matched controls (NC) were analyzed for uric acid (UA), dopamine (DA), and ascorbic acid (AA) by HPLC/UV/ED. Uric acid and DA levels were significantly lower in the substantia nigra of PD by 54% and 85%, respectively. In the caudate, DA levels were significantly lower while UA levels were nonsignificantly reduced (0.10 < p < 0.05). Ascorbic acid levels were not significantly different from the controls in either brain region. Conditions favorable for oxidative stress were evaluated by measuring the oxidation of DA in individual brain homogenates. The rate constant for DA oxidation in control caudate was 0.34 x 10(-2) min-1 and in parkinsonian caudate was 4.20 x 10(-2) min-1. In control and parkinsonian substantia nigra DA oxidation rate constants were 2.82 x 10(-2) min-1 and 4.57 x 10(-2) min-1, respectively. Addition of UA or catalase to parkinsonian homogenate decreased the rate of DA oxidation, while addition of uricase to control homogenate increased the rate of DA oxidation. The data support the hypothesis that UA is decreased in nigrostriatal dopamine neurons in parkinsonian patients which contributes to an environment susceptible to oxidative stress, particularly through dopamine oxidation reactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8124580     DOI: 10.1016/0361-9230(94)90285-2

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  59 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease.

Authors:  Eugeniu Vieru; Ayhan Köksal; Belgin Mutluay; Ayten Ceyhan Dirican; Yavuz Altunkaynak; Sevim Baybas
Journal:  Neurol Sci       Date:  2016-01-11       Impact factor: 3.307

3.  Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.

Authors:  Jeffrey K Yao; George G Dougherty; Ravinder D Reddy; Matcheri S Keshavan; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

4.  Uric acid protects against secondary damage after spinal cord injury.

Authors:  Gwen S Scott; Salvatore Cuzzocrea; Tiziana Genovese; Hilary Koprowski; D Craig Hooper
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

5.  Serum Uric Acid and Its Association with Longitudinal Cognitive Change Among Urban Adults.

Authors:  May A Beydoun; Jose-Atilio Canas; Gregory A Dore; Hind A Beydoun; Ola S Rostant; Marie T Fanelli-Kuczmarski; Michele K Evans; Alan B Zonderman
Journal:  J Alzheimers Dis       Date:  2016-04-21       Impact factor: 4.472

Review 6.  Targeting urate to reduce oxidative stress in Parkinson disease.

Authors:  Grace F Crotty; Alberto Ascherio; Michael A Schwarzschild
Journal:  Exp Neurol       Date:  2017-06-13       Impact factor: 5.330

7.  Basal ganglia dopamine loss due to defect in purine recycling.

Authors:  Kiyoshi Egami; Silaja Yitta; Suhail Kasim; J Chris Lewers; Rosalinda C Roberts; Mohamed Lehar; H A Jinnah
Journal:  Neurobiol Dis       Date:  2007-02-08       Impact factor: 5.996

8.  Toxicity of dopamine and dopaminochrome on cultured cells.

Authors:  L Galzigna; L Zanatta; N Esposito
Journal:  Neurotox Res       Date:  1999-12       Impact factor: 3.911

9.  Gout and the risk of Parkinson's disease in Denmark.

Authors:  Eva Schernhammer; Jiaheng Qiu; Lene Wermuth; Christina Funch Lassen; Soren Friis; Beate Ritz
Journal:  Eur J Epidemiol       Date:  2013-03-02       Impact factor: 8.082

10.  Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration.

Authors:  Xiqun Chen; Thomas C Burdett; Cody A Desjardins; Robert Logan; Sara Cipriani; Yuehang Xu; Michael A Schwarzschild
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.